I've been looking at some of the best cannabis stocks to buy lately, and honestly, most people are fixated on the wrong names. Everyone talks about Tilray Brands when discussing marijuana investments, but if you dig into the numbers, something feels off.

Tilray started as a pure-play cannabis company, but over the years they've pivoted hard. They're now trying to position themselves as this brand manager across marijuana, CBD, and alcohol. Sounds good on paper, right? Here's the catch though—they've been funding all these acquisitions with stock, which has dilated shareholders to hell. Their share count has ballooned over 300% in five years, and they're still not profitable. Even worse, they've taken impairment charges across basically every business segment. That tells you something about how well this pivot is actually working.

But here's where it gets interesting. If you're going to take a swing at sin stocks with actual cash flow, there's a better play: Altria. I know, I know—tobacco sounds boring and dying. And it is declining. But that's exactly why the cash flow is so insane. Marlboro alone commands 40.5% of the U.S. cigarette market as of 2025, and Altria's total cigarette share sits at 45.2%. That's a fortress position.

The real story is what they're doing with all that cash. They're running a 6.1% dividend yield while simultaneously investing in new products to eventually replace cigarettes. They've had some stumbles—the Juul investment didn't work out, and their early marijuana bet fizzled. But here's the difference: they were strong enough to absorb those losses and keep swinging. They just picked up vape maker NJOY and are clearly still hunting for the next big thing.

Now, is Altria risky? Absolutely. Their core business is in structural decline. But there's a massive difference between declining cash flows and no cash flows. Tilray is still trying to figure out if they can ever make money. Altria is literally printing cash from their existing business while they build what comes next.

If you're shopping for the best cannabis stocks to buy or any sin stock really, the risk-reward just tilts differently. With Tilray, you're betting they eventually find a working model. With Altria, you're betting they can deploy their cash generation smartly enough to offset the cigarette decline. One of those feels a lot more concrete to me, especially when you're getting paid 6.1% to wait and see how it plays out.

That said, neither of these is for the faint of heart. You need to stay on top of what management is actually doing with the business. But if you're going to take educated risks in this space, the choice seems pretty clear.